Alzheimer's disease (AD) is a neurodegenerative disorder primarily characterized by progressive cognitive impairment and neuronal damage. The pathogenesis of AD is complex and involves multiple pathological processes. Currently, effective methods for early diagnosis and treatment are lacking.
Objective
To identify key pathogenic genes and investigate their roles in Alzheimer's disease, we analyzed transcriptomic data from dermal fibroblasts of AD patients, aiming to assess their potential as novel biomarkers and therapeutic targets.
Methods
Transcriptomic data from AD patient and control-derived dermal fibroblasts (DFs) were analyzed to identify differentially expressed genes. Key genes were screened using bioinformatics and a random forest algorithm. ceRNA analysis was performed to explore miRNA-mRNA interactions. The candidate gene SRSF5 was validated via overexpression and knockdown, followed by qPCR, western blotting, and reactive oxygen species (ROS) assays. The role of SRSF5 in endoplasmic reticulum (ER) stress was evaluated by measuring ER stress markers and cellular stress responses.
Results
Transcriptomic analysis revealed significant upregulation of SRSF5 in AD DFs. ceRNA analysis identified miRNAs regulating SRSF5 in AD. Overexpression of SRSF5 led to reduced neuronal proliferation, increased apoptosis, elevated ROS levels, and activation of ER stress markers (CHOP, GRP78, XBP1). SRSF5 knockdown alleviated these effects.
Conclusions
SRSF5 may drive AD pathogenesis via ER and oxidative stress, serving as a potential biomarker and therapeutic target for early diagnosis and intervention.
VejandlaBSavaniSAppalaneniR, et al.Alzheimer's disease: the past, present, and future of a globally progressive disease. Cureus2024; 16: e51705.
3.
QinH. Amyloid-β and neurodegeneration: pathological mechanisms and therapeutic challenges in Alzheimer’s disease. Highlights Sci Eng Technol2025; 144: 77–82.
4.
Valverde-SalazarVRuiz-GabarreDGarcía-EscuderoV. Alzheimer’s disease and green tea: epigallocatechin-3-gallate as a modulator of inflammation and oxidative stress. Antioxidants2023; 12: 1460.
5.
UddinMSYuWSLimLW. Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer's disease. Ageing Res Rev2021; 70: 101417.
6.
SalehROJabirMSMohammedJS, et al.Exploring the endoplasmic reticulum's role in Alzheimer's disease and its potential as a therapeutic target. J Biochem Mol Toxicol2025; 39: e70405.
7.
VyhnalekMLaczóMLaczóJ. Diagnosis of Alzheimer’s disease in clinical practice: time to incorporate biomarkers?J Alzheimers Dis2024; 101: 1133–1136.
8.
KimJJeongMStilesWR, et al.Neuroimaging modalities in Alzheimer’s disease: diagnosis and clinical features. Int J Mol Sci2022; 23: 6079.
9.
PomeshchikYVelasquezEGilJ, et al.Proteomic analysis across patient iPSC-based models and human post-mortem hippocampal tissue reveals early cellular dysfunction and progression of Alzheimer's disease pathogenesis. Acta Neuropathol Commun2023; 11: 150.
10.
ElmanJASchorkNJRanganAV, et al.Exploring the genetic heterogeneity of Alzheimer’s disease: evidence for genetic subtypes. J Alzheimers Dis2024; 100: 1209–1226.
11.
ParvishanAJoghataeiMTKianiJ, et al.Generation of human-induced pluripotent stem cells derived from dermal fibroblast of schizophrenic patients. Basic Clin Neurosci2024; 15: 333–342.
12.
QuWCanollPHargusG. Molecular insights into cell type-specific roles in Alzheimer’s disease: human induced pluripotent stem cell-based disease modelling. Neuroscience2023; 518: 10–26.
13.
KimYNam YJYoonS, et al.Transcriptional landscape and biomarker discovery for endoplasmic reticulum stress in Alzheimer's disease: an ex vivo study using patients-derived dermal fibroblasts. Psychiatry Investig2025; 22: 699–713.
14.
Ritchie MEPhipsonBWuD, et al.Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res2015; 43: e47.
15.
ShenWSongZZhongX, et al.Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta2022; 1: e36.
16.
BreimanL. Random forests. Mach Learn2001; 45: 5–32.
17.
MasiMAttanzioARacchiM, et al.Proteostasis deregulation in neurodegeneration and its link with stress granules: focus on the scaffold and ribosomal protein RACK1. Cells2022; 11: 2590.
18.
ThapaRAhmad BhatAShahwanM, et al.Proteostasis disruption and senescence in Alzheimer's disease pathways to neurodegeneration. Brain Res2024; 1845: 149202.
19.
OuGYLinWWZhaoWJ. Construction of long noncoding RNA-associated ceRNA networks reveals potential biomarkers in Alzheimer's disease. J Alzheimers Dis2021; 82: 169–183.
20.
SabaieHAmirinejadNAsadiMR, et al.Molecular insight into the therapeutic potential of long non-coding RNA-associated competing endogenous RNA axes in Alzheimer's disease: a systematic scoping review. Front Aging Neurosci2021; 13: 742242.
21.
LiJLiGQiY, et al.SRSF5 Regulates alternative splicing of DMTF1 pre-mRNA through modulating SF1 binding. RNA Biol2021; 18: 318–336.
22.
GhemrawiRKhairM. Endoplasmic reticulum stress and unfolded protein response in neurodegenerative diseases. Int J Mol Sci2020; 21: 6127.
23.
AjoolabadyALindholmDRenJ, et al.ER Stress and UPR in Alzheimer’s disease: mechanisms, pathogenesis, treatments. Cell Death Dis2022; 13: 706.
24.
LiuNLiangXChenY, et al.Recent trends in treatment strategies for Alzheimer's disease and the challenges: a topical advancement. Ageing Res Rev2024; 94: 102199.
25.
RenJBiYSowersJR, et al.Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases. Nat Rev Cardiol2021; 18: 499–521.
26.
ChenSChenJHuaX, et al.The emerging role of XBP1 in cancer. Biomed Pharmacother2020; 127: 110069.
27.
El ManaaWDuplanEGoiranT, et al.Transcription- and phosphorylation-dependent control of a functional interplay between XBP1 s and PINK1 governs mitophagy and potentially impacts Parkinson disease pathophysiology. Autophagy2021; 17: 4363–4385.
28.
OlufunmilayoEOHolsingerRM. Roles of non-coding RNA in Alzheimer’s disease pathophysiology. Int J Mol Sci2023; 24: 12498.
29.
HsiehY-CGuoCYalamanchiliHK, et al.Tau-mediated disruption of the spliceosome triggers cryptic RNA splicing and neurodegeneration in Alzheimer’s disease. Cell Rep2019; 29: 301–316.e10.
30.
van der LindenRJGerritsenJSLiaoM, et al.RNA-binding protein ELAVL4/HuD ameliorates Alzheimer's disease-related molecular changes in human iPSC-derived neurons. Prog Neurobiol2022; 217: 102316.
31.
LiHCaiLLiangM, et al.Methionine augments endogenous antioxidant capacity of rice protein through stimulating MSR antioxidant system and activating Nrf2-ARE pathway in growing and adult rats. Eur Food Res Technol2020; 246: 1051–1063.
32.
Di MeoSNapolitanoGVendittiP. Mediators of physical activity protection against ROS-linked skeletal muscle damage. Int J Mol Sci2019; 20: 3024.
33.
NordziekeDEMedraño-FernandezI. The plasma membrane: a platform for intra- and intercellular redox signaling. Antioxidants2018; 7: 168.
34.
GognaTHousdenBEHouldsworthA. Exploring the role of reactive oxygen species in the pathogenesis and pathophysiology of Alzheimer’s and Parkinson’s disease and the efficacy of antioxidant treatment. Antioxidants2024; 13: 1138.
35.
HeCLiZYangM, et al.Non-coding RNA in microglia activation and neuroinflammation in Alzheimer’s disease. J Inflamm Res2023; 16: 4165–4211.
36.
NovoaCSalazarPCisternasP, et al.Inflammation context in Alzheimer’s disease, a relationship intricate to define. Biol Res2022; 55: 39.
37.
DhapolaRHotaSSSarmaP, et al.Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease. Inflammopharmacology2021; 29: 1669–1681.
38.
FuYWangYZhangL, et al.SRSF3 Knockdown inhibits lipopolysaccharide-induced inflammatory response in macrophages. Curr Issues Mol Biol2024; 46: 6237–6247.
39.
KongFWuTDaiJ, et al.Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies. Front Pharmacol2023; 14: 1205207.
40.
UrkonMFerenczESzászJA, et al.Antidiabetic GLP-1 receptor agonists have neuroprotective properties in experimental animal models of Alzheimer's disease. Pharmaceuticals (Basel)2025; 18: 614.
41.
ZhangPMaoCSunA, et al.Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease. Alzheimers Dement2025; 21: e70639.
42.
LiangYDoréVRoweCC, et al.Clinical evidence for GLP-1 receptor agonists in Alzheimer's disease: a systematic review. J Alzheimers Dis Rep2024; 8: 777–789.
43.
NehmehBRebehmedJNehmehR, et al.Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases. Drug Discov Today2024; 29: 104216.
44.
EkinsSLaneTR. Applications of artificial intelligence in drug discovery for neurological diseases. Neurotherapeutics2025; 22: e00624.
45.
SurianarayananCLawrenceJJChelliahPR, et al.Convergence of artificial intelligence and neuroscience towards the diagnosis of neurological disorders-a scoping review. Sensors (Basel)2023; 23: 3062.
